NKGen Biotech transitions CSO Yong Man Kim to consulting role, retains scientific leadership

NKGen Biotech, Inc.

Yong Man Kim becomes independent contractor as CSO; previously an employee.
Agreement effective September 25, 2025; at-will termination by either party.
Kim will provide at least 8 hours/week (20% working time) on R&D consulting.
Kim also serves as President of NKMax; NKGen retains his expertise.
No cash compensation disclosed; consideration is access to IP and confidential info.

item 1.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.